What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment.
about
Prevalence and patterns of antidepressant switching amongst primary care patients in the UK.Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.
P2860
What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What happens next?: a claims d ...... ke inhibitor (SSRI) treatment.
@en
What happens next?: a claims d ...... with major depressive disorder
@nl
type
label
What happens next?: a claims d ...... ke inhibitor (SSRI) treatment.
@en
What happens next?: a claims d ...... with major depressive disorder
@nl
prefLabel
What happens next?: a claims d ...... ke inhibitor (SSRI) treatment.
@en
What happens next?: a claims d ...... with major depressive disorder
@nl
P2093
P2860
P921
P356
P1476
What happens next?: a claims d ...... ke inhibitor (SSRI) treatment.
@en
P2093
Ellen B Dennehy
Peter Classi
Susan Ball
P2860
P2888
P356
10.1186/1744-859X-13-8
P577
2014-03-19T00:00:00Z
P6179
1038406291